Sweet Demand: How Weight-Loss Drugs Are Boosting Chocolate Sales

Chocolate sales are unexpectedly rising among U.S. consumers of GLP-1 weight-loss drugs like Ozempic and Mounjaro, defying expectations. Lindt & Spruengli reports that GLP-1 users account for a significant portion of premium chocolate sales, as consumers seek small indulgences rather than cutting out all high-calorie products.

Unexpected trends are unfolding in the confectionery sector, with chocolate sales experiencing a surge among U.S. users of GLP-1 weight-loss drugs, according to Swiss chocolatier Lindt & Spruengli. This revelation, based on February data from market researcher Circana, challenges predictions that these drugs would lead to decreased demand for confectionery items.

The company's study indicates that 15% of U.S. households are using GLP-1s, responsible for 17.5% of chocolate sales. Weight-loss drugs like Novo Nordisk's Ozempic and Eli Lilly's Mounjaro are included in this category. The trend reflects a shift towards premium indulgences as consumers cut back on high-calorie products like pasta and pizza, explains Lindt CEO Adalbert Lechner.

Contrary to analysts' expectations for future declines in chocolate sales, Lechner remains optimistic. Lindt anticipates a similar influence in Europe following regulatory approvals. The expansion of oral GLP-1 pills is expected to broaden the user base beyond injectables, attracting more men and younger adults, which could continue to foster robust chocolate consumption.

(With inputs from agencies.)